6-巯基烟酸 | 17624-07-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-巯基烟酸
• 中文别名: 6-巯基类酸；6-硫氧代-1,6-二氢吡啶-3-羧酸；N-苄基-3-氧代哌啶-4-羧酸乙酯
• 英文名称: 6-Mercapto-nicotinic acid
• 英文别名: 6-mercaptopyridine-3-carboxylic acid；6-sulfanylidene-1H-pyridine-3-carboxylic acid
• CAS: 17624-07-6
• 化学式: C₆H₅NO₂S
• 分子量: 155.177
• InChiKey: JWWGTYCXARQFOT-UHFFFAOYSA-N

物化性质

• 熔点：
  260-262 °C (dec.)(lit.)
• 沸点：
  259.9±50.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  6-巯基烟酸 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 27.0h， 生成 (6-(2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzylthio)nicotinic)pivalic anhydride
  参考文献：
  名称：

  Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2

  摘要：

  The G protein-coupled chemokine receptors CXCR1 and CXCR2 play key roles in inflammatory diseases and carcinogenesis. In inflammation, they activate and recruit polymorphonuclear cells (PMNs) through binding of the chemokines CXCL1 (CXCR1) and CXCL8 (CXCR1 and CXCR2). Structure-activity studies that examined the effect of a novel series of S-substituted 6-mercapto-N-phenyl-nicotinamides on CXCL1-stimulated Ca2+ flux in whole human PMNs led to the discovery of 2-[5-(4-fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517), a potent noncompetitive boronic acid CXCR1/2 antagonist. SX-517 inhibited CXCL1-induced Ca2+ flux (IC50 = 38 nM) in human PMNs but had no effect on the Ca2+ flux induced by C5a, fMLF, or PAF. In recombinant HEK293 cells that stably expressed CXCR2, SX-517 antagonized CXCL8-induced [S-35]GTP?S binding (IC50 = 60 nM) and ERK1/2 phosphorylation. Inhibition was noncompetitive, with SX-517 unable to compete the binding of [I-125]-CXCL8 to CXCR2 membranes. SX-517 (0.2 mg/kg iv) significantly inhibited inflammation in an in vivo murine model. SX-517 is the first reported boronic acid chemokine antagonist and represents a novel pharmacophore for CXCR1/2 antagonism.

  DOI：

  10.1021/jm500827t
• 作为产物：
  描述：

  6,6ˊ-二硫二烟酸 在 sodium citrate 、 三氯化钛 作用下， 以 乙醇 、 水 、 溶剂黄146 为溶剂， 以30%的产率得到6-巯基烟酸
  参考文献：
  名称：

  Akers, Hugh A.; Vang, Meng C.; Updike, Tracie D., Canadian Journal of Chemistry, 1987, vol. 65, p. 1364 - 1366

  摘要：

  DOI：

文献信息

• [EN] CRBN LIGANDS AND USES THEREOF<br/>[FR] LIGANDS CRBN ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2019140387A1

  公开（公告）日：2019-07-18

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物抑制CRBN并治疗CRBN介导的疾病的方法。
• Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators
  申请人：Maeda Dean Y.

  公开号：US20100210593A1

  公开（公告）日：2010-08-19

  There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.

  披露了作为药物剂的吡啶和嘧啶羧酰胺化合物，合成过程以及包括吡啶和嘧啶羧酰胺化合物的药物组合物。更具体地，披露了一类CXCR2抑制剂化合物，可用于治疗各种炎症和肿瘤性疾病。
• [EN] HEPATITIS C INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE L'HÉPATITE C
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013026163A1

  公开（公告）日：2013-02-28

  A compound of formula (I) useful for the treatment or prevention of hepatitis C viral infection, (Formula (I)) wherein: X1 and X2 are each independently CRB or N; RB is H, (C1-6)alkyl, (C1-6)haloalkyl, halo. -O-(C1-6)alkyl, NH2, NH(C1-6)alkyl or N((C1-6)alkyl)2; R1 and R2 are each independently (C1-6)alkyl optionally mono- or di-substituted with -O-(C1-6)alkyl, NH2, NH(C1-6)alkyl or N((C1-6)alkyl)2; or R1 and R2, together with the carbon to which they are attached, are linked to form a (C3-7)cycloalkyl group or a 3- to 7-membered heterocyclyl, said cycloalkyl and heterocyclyl being optionally mono- or di-substituted with -(C1-6)alkyl; RA is -C(=O)N(R3)(R4), -C(=O)O(R4), heterocyclyl or heteroaryl, wherein each said heterocyclyl and heteroaryl is optionally substituted 1 to 3 times with R41; R5 and R6 are each independently H or (C1-6)alkyl optionally mono- or di-substituted with -O-(C1-6)alkyl, NH2, NH(C1-6)alkyl or N((C1-6)alkyl)2; or R5 and R6, together with the carbon to which they are attached, are linked to form a (C3-7)cycloalkyl group or a 3- to 7-membered heterocyclyl, said cycloalkyl and heterocyclyl being optionally mono- or di-substituted with -(C1-6)alkyl; and n is 0, 1 or 2.

  一种化合物，其化学式为（I），用于治疗或预防丙型肝炎病毒感染，其中：X1和X2分别独立地为CRB或N；RB为H，（C1-6）烷基，（C1-6）卤代烷基，卤基，-O-（C1-6）烷基，NH2，NH（C1-6）烷基或N（（C1-6）烷基）2；R1和R2分别独立地为（C1-6）烷基，可选择地单取代或双取代为-O-（C1-6）烷基，NH2，NH（C1-6）烷基或N（（C1-6）烷基）2；或者R1和R2与它们连接的碳原子一起形成（C3-7）环烷基或3-至7-成员杂环烷基，所述环烷基和杂环烷基可选择地单取代或双取代为-（C1-6）烷基；RA为-C（=O）N（R3）（R4），-C（=O）O（R4），杂环烷基或杂芳基，其中每个所述杂环烷基和杂芳基可选择地用R41取代1至3次；R5和R6分别独立地为H或（C1-6）烷基，可选择地单取代或双取代为-O-（C1-6）烷基，NH2，NH（C1-6）烷基或N（（C1-6）烷基）2；或者R5和R6与它们连接的碳原子一起形成（C3-7）环烷基或3-至7-成员杂环烷基，所述环烷基和杂环烷基可选择地单取代或双取代为-（C1-6）烷基；n为0、1或2。
• Condensed imidazole derivatives
  申请人：Eisai Co., Ltd.

  公开号：US20040116328A1

  公开（公告）日：2004-06-17

  The present invention is related to compounds represented by the following formula, or salts or hydrates thereof 1 wherein, T 1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C 1-6 alkyl group which may have one or more substituents, or such; Z 1 and Z 2 each independently represent a nitrogen atom or a group represented by the formula —CR 2 —; R 1 and R 2 independently represent a hydrogen atom, a C 1-6 alkyl group which may have one or more substituents, or a C 1-6 alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.

  本发明涉及以下公式所代表的化合物，或其盐或水合物 其中， T 1 代表一个含有一个或两个氮原子的4-至12-成员杂环基团，在环中是单环或双环结构，可能具有一个或多个取代基; X代表一个C 1-6 烷基基团，可能具有一个或多个取代基，或类似物; Z 1 和Z 2 各自独立地代表一个氮原子或由公式—CR 2 —所代表的基团; R 1 和R 2 独立地代表氢原子，一个C 1-6 烷基基团，可能具有一个或多个取代基，或一个C 1-6 烷氧基基团，可能具有一个或多个取代基，或类似物。 这些是表现出优异DPPIV抑制活性的新颖化合物。
• [EN] TRIAZINE-OXADIAZOLES<br/>[FR] TRIAZINE-OXADIAZOLES
  申请人：NOVARTIS AG

  公开号：WO2012035023A1

  公开（公告）日：2012-03-22

  The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of chronic pain.

  这项发明涉及公式（I）的新衍生物，其中取代基如规范中所定义；制备这种衍生物的方法；包括这种衍生物的药物组合物；将这种衍生物用作药物；将这种衍生物用于治疗慢性疼痛。